AJP - Endo Watch the video to see how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 277: E617-E623, 1999;
0193-1849/99 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Broca, C.
Right arrow Articles by Ribes, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Broca, C.
Right arrow Articles by Ribes, G.
Vol. 277, Issue 4, E617-E623, October 1999

4-Hydroxyisoleucine: experimental evidence of its insulinotropic and antidiabetic properties

Christophe Broca1,2, René Gross1, Pierre Petit2, Yves Sauvaire2, Michèle Manteghetti1, Michel Tournier2, Pellegrino Masiello3, Ramon Gomis4, and Gérard Ribes1

1 Unité Mixte de Recherche 9921 du Centre National de la Recherche Scientifique, and 2 Laboratoire de Pharmacologie, Faculté de Médecine and Laboratoire deRecherche sur les Substances Naturelles Végétales, UPRES EA 1677, 34060 Montpellier, France; 3 Istituto di Patologia Generale, University of Pisa, Italy; and 4 Endocrinology Unit, Hospital Clinic, 08036 Barcelona, Spain

We have recently shown in vitro that 4-hydroxyisoleucine (4-OH-Ile), an amino acid extracted from fenugreek seeds, potentiates insulin secretion in a glucose-dependent manner. The present study was designed to investigate whether 4-OH-Ile could exert in vivo insulinotropic and antidiabetic properties. For this purpose, intravenous or oral glucose tolerance tests (IVGTTs and OGTTs, respectively) were performed not only in normal animals but also in a type II diabetes rat model. During IVGTT in normal rats or OGTT in normal dogs, 4-OH-Ile (18 mg/kg) improved glucose tolerance. The lactonic form of 4-OH-Ile was ineffective in normal rats. In non-insulin-dependent diabetic (NIDD) rats, a single intravenous administration of 4-OH-Ile (50 mg/kg) partially restored glucose-induced insulin response without affecting glucose tolerance; a 6-day subchronic administration of 4-OH-Ile (50 mg/kg, daily) reduced basal hyperglycemia, decreased basal insulinemia, and slightly, but significantly, improved glucose tolerance. In vitro, 4-OH-Ile (200 µM) potentiated glucose (16.7 mM)-induced insulin release from NIDD rat-isolated islets. So, the antidiabetic effects of 4-OH-Ile on NIDD rats result, at least in part, from a direct pancreatic B cell stimulation.

antidiabetic agent; insulin secretion; type II diabetes rat model; glucose tolerance


This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
C. Broca, V. Breil, C. Cruciani-Guglielmacci, M. Manteghetti, C. Rouault, M. Derouet, S. Rizkalla, B. Pau, P. Petit, G. Ribes, et al.
Insulinotropic agent ID-1101 (4-hydroxyisoleucine) activates insulin signaling in rat
Am J Physiol Endocrinol Metab, September 1, 2004; 287(3): E463 - E471.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online